Filing Details

Accession Number:
0001104659-23-122540
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-12-01 06:01:38
Reporting Period:
2023-11-29
Accepted Time:
2023-12-01 06:01:38
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1763950 Lantern Pharma Inc. LTRN () TX
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1697316 Bios Fund I, Lp C/O Lantern Pharma Inc.
1920 Mckinney Avenue, 7Th Floor
Dallas TX 75201
No No Yes No
1700297 Bios Fund I Qp, Lp C/O Lantern Pharma Inc.
1920 Mckinney Avenue, 7Th Floor
Dallas TX 75201
No No Yes No
1714576 Bios Fund Ii, Lp C/O Lantern Pharma Inc.
1920 Mckinney Avenue, 7Th Floor
Dallas TX 75201
No No Yes No
1716869 Bios Fund Ii Qp, Lp C/O Lantern Pharma Inc.
1920 Mckinney Avenue, 7Th Floor
Dallas TX 75201
No No Yes No
1728851 Bios Fund Ii Nt, Lp C/O Lantern Pharma Inc.
1920 Mckinney Avenue, 7Th Floor
Dallas TX 75201
No No Yes No
1789490 G.l. Aaron Fletcher C/O Lantern Pharma Inc.
1920 Mckinney Avenue, 7Th Floor
Dallas TX 75201
No No Yes No
1813313 Bios Equity Partners Ii, Lp C/O Lantern Pharma Inc.
1920 Mckinney Avenue, 7Th Floor
Dallas TX 75201
No No Yes No
1813314 Bios Equity Partners, Lp C/O Lantern Pharma Inc.
1920 Mckinney Avenue, 7Th Floor
Dallas TX 75201
No No Yes No
1813844 Bios Advisors Gp, Llc C/O Lantern Pharma Inc.
1920 Mckinney Avenue, 7Th Floor
Dallas TX 75201
No No Yes No
1813845 Bios Capital Management, Lp C/O Lantern Pharma Inc.
1920 Mckinney Avenue, 7Th Floor
Dallas TX 75201
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-11-29 53,640 $3.44 217,553 No 4 S Indirect By Bios Fund I QP, LP
Common Stock Disposition 2023-11-29 91,708 $3.44 371,950 No 4 S Indirect By Bios Fund I, LP
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect By Bios Fund I QP, LP
No 4 S Indirect By Bios Fund I, LP
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 71,774 Indirect By Bios Fund II NT, LP
Common Stock 536,163 Indirect By Bios Fund II QP, LP
Common Stock 164,137 Indirect By Bios Fund II, LP
Common Stock 26,093 Indirect By BP Directors, LP
Footnotes
  1. On November 22, 2023, Lantern Pharma Inc. (the "Issuer") purchased 53,640 and 91,708 shares of common stock from Bios Fund I QP, LP ("Bios Fund I QP") and Bios Fund I, LP ("Bios Fund I"), respectively, for an aggregate purchase price of $529,828.80. These purchases were approved by the board of directors of the Issuer.
  2. Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP") and Bios Fund II NT, LP ("Bios Fund II NT"). Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Mr. Kreis, and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management.
  3. Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities.
  4. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.